• Investors
  • Careers
  • Contact Us
  • About Us
  • Our Products
  • Our Pipeline
  • Our Technology

Stock

Nasdaq:
DEPO
Price:
6.03 +0.11
Volume:
306,471
20 minute delay

In The News

January 24, 2012 Depomed Announces Initiation of Phase 2 Clinical Study in Parkinson's Disease
January 23, 2012 Depomed Receives Notice of Paragraph IV Certification Against Patents for Gralise(TM)
December 20, 2011 Depomed Names August J. Moretti as Chief Financial Officer
November 8, 2011 Depomed to Present at Lazard Capital Markets Healthcare Conference
November 1, 2011 Depomed Reports Third Quarter 2011 Financial Results
  • Home
  • About Us
  • Our Products
  • Our Pipeline
  • Our Technology
  • Investors
  • Careers
  • Contact Us
  • Sitemap
  • Terms of Use
  • Privacy Policy
© Depomed Inc, All rights reserved. Website design by Hane Chow, Inc.